Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeannin, E.
Right arrow Articles by Desvergne, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeannin, E.
Right arrow Articles by Desvergne, B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 37, 24239-24248, September 11, 1998


Transcriptional Regulatory Patterns of the Myelin Basic Protein and Malic Enzyme Genes by the Thyroid Hormone Receptors alpha 1 and beta 1*

Elisabeth Jeannin, Daniel Robyr, and Béatrice DesvergneDagger

From the Institut de Biologie Animale, Université de Lausanne, Bâtiment de Biologie, CH-1015 Lausanne, Switzerland

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

While there is evidence that the two ubiquitously expressed thyroid hormone (T3) receptors, TRalpha 1 and TRbeta 1, have distinct functional specificities, the mechanism by which they discriminate potential target genes remains largely unexplained. In this study, we demonstrate that the thyroid hormone response elements (TRE) from the malic enzyme and myelin basic protein genes (METRE and MBPTRE) respectively, are not functionally equivalent. The METRE, which is a direct repeat motif with a 4-base pair gap between the two half-site hexamers binds thyroid hormone receptor as a heterodimer with 9-cis-retinoic acid receptor (RXR) and mediates a high T3-dependent activation in response to TRalpha 1 or TRbeta 1 in NIH3T3 cells. In contrast, the MBPTRE, which consists of an inverted palindrome formed by two hexamers spaced by 6 base pairs, confers an efficient transactivation by TRbeta 1 but a poor transactivation by TRalpha 1. While both receptors form heterodimers with RXR on MBPTRE, the poor transactivation by TRalpha 1 correlates also with its ability to bind efficiently as a monomer. This monomer, which is only observed with TRalpha 1 bound to MBPTRE, interacts neither with N-CoR nor with SRC-1, explaining its functional inefficacy. However, in Xenopus oocytes, in which RXR proteins are not detectable, the transactivation mediated by TRalpha 1 and TRbeta 1 is equivalent and independent of a RXR supply, raising the question of the identity of the thyroid hormone receptor partner in these cells. Thus, in mammalian cells, the binding characteristics of TRalpha 1 to MBPTRE (i.e. high monomer binding efficiency and low transactivation activity) might explain the particular pattern of T3 responsiveness of MBP gene expression during central nervous system development.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Thyroid hormone receptors (TRs)1 are transcription factors that belong to the steroid/thyroid nuclear receptor superfamily, which are encoded by two distinct genes, c-erbAalpha and c-erbAbeta . Alternative splicing of the alpha  gene primary transcripts at their 3' extremity generates mRNAs encoding TRalpha 1, which binds thyroid hormone (triiodothyronine; T3), as well as the c-erbAalpha 2 and c-erbAalpha 3 variants, which do not. The beta  gene expresses two T3-binding isoforms, TRbeta 1 and the minor form TRbeta 2 (reviewed in Ref. 1). In the adult animal, the alpha 1 and beta 1 receptor mRNAs are found in all T3-sensitive tissues, albeit with differences in their relative abundance (2, 3). In contrast, expression of the two receptor isotypes is strikingly different during brain development. Whereas TRalpha 1 expression predominates at early stages and remains steady, TRbeta 1 expression is initially very low but exhibits a dramatic transient increase during the critical period of the central nervous system maturation (4-6). At this moment, beta 1 transcripts prevail in the proliferation layer, while those of alpha 1 are localized in the differentiation layer of the developing rat cerebral cortex. These patterns of expression are consistent with specific functions of the two receptors in brain development (7-9).

TR transactivation activities are mediated through binding to specific DNA elements called thyroid hormone response elements (TREs) present in the promoter of target genes. TREs are composed of two hexameric half-sites closely related to the consensus AGGTCA, arranged either as a direct repeat (DR), or as palindromic or inverted palindromic (IP) arrays (10). An intriguing feature of TRs is their ability to interact with these TREs as monomer, homodimer, or heterodimer with the 9-cis-retinoic acid receptor (RXR). The relatively high binding affinity of the TR/RXR heterodimer for the TREs (11-17), the broad expression of RXR (18-20), and the requirement of RXR for in vitro ligand-dependent transcription by TRs (21) emphasize the predominant role of this heterodimer in transcription activation. In contrast, the role of TR homodimers that are disrupted upon T3 addition in in vitro binding assays (22-24) and that of TR monomers whose binding requires an extended TRE half-site are not yet elucidated. The recent identification of nuclear receptor co-repressors and co-activators suggests that TR-mediated transcriptional regulation is a stepwise process. It is thought that, in the absence of T3, TR/RXR binds to the TRE and represses basal promoter activity by interacting with silencing factors such as N-CoR and SMRT (25, 26). The addition of T3 would release co-repressors, thereby allowing the interaction of the receptors with co-activators such as SRC-1 and p300/CBP (27, 28). Thus, transactivation of target genes would consist of both a derepression and then a further stimulation of the target promoter.

While there is evidence for specific roles of TRalpha 1 and TRbeta 1 in mediating T3 effects as mentioned above, the mechanism by which the two receptors discriminate between specific target genes remains largely unexplained. To address this question, we analyzed two T3-regulated genes, the malic enzyme (ME) and the myelin basic protein (MBP) genes. The ME gene is involved in lipid metabolism, more particularly in lipid synthesis. Its expression is ubiquitous but is up-regulated by T3 in rat liver, kidney, and heart. So far, no specific developmental expression pattern of this gene has been described. The product of the second gene studied herein, MBP, is a major protein constituent of the myelin sheet surrounding the axons. Expression of this gene is nervous system-specific and developmentally regulated. Up-regulation by T3 is mainly observed during the high myelinating activity at the critical period of brain maturation (29). Interestingly, the onset of myelination is marked by transiently elevated levels of TRbeta 1 mRNA that parallel those of MBP mRNA, suggesting the involvement of TRbeta 1 in the regulated expression of the MBP gene (30). Moreover, when analyzed in a reporter gene transfection assay, TRbeta 1 is a more potent T3-dependent inducer of the MBP promoter activity than TRalpha 1. In contrast, the ME promoter is more efficiently stimulated by TRalpha 1 as compared with TRbeta 1 in response to T3 (31). This differential regulation of these two genes by TRalpha 1 and TRbeta 1 is thus physiologically relevant and provides a model to gain insight into the mechanisms of TR isotype-specific action.

In this study, we demonstrate that in NIH3T3 cells the TREs of the ME and MBP genes (METRE and MBPTRE) are not functionally equivalent. The METRE, which is a direct repeat motif with a 4-base pair gap between two hexamers (DR4, Fig. 1A) (32), mediates high T3-dependent response by both TRalpha 1 and TRbeta 1. In contrast, the MBPTRE, which consists of an inverted palindrome formed by two hexamers spaced by 6 base pairs (IP6, Fig. 1A) (31), confers a poor TRalpha 1-mediated transactivation as compared with TRbeta 1. This poor TRalpha 1 activity correlates with its ability to efficiently bind the MBPTRE as monomer. We thus further explored the characteristics of the TRalpha 1 monomer in terms of DNA sequence requirements, functional properties, and co-factor interactions.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Plasmids-- The construction of chloramphenicol acetyltransferase (CAT) reporter genes, MBP(-256/+3)-CAT and ME(-315/+3)-CAT, has been previously described (29, 33), and these genes are here referred to as MBP-256 and ME-315, respectively. The MBP/METRE and the MBP-256/5'm reporter gene were obtained by PCR mutagenesis of the MBP-256 reporter according to the protocol described for PCR technology (34). The following primers were used for the MBP-256/5'm construct: MBP-187(+), 5'-AATGTTGAACGAGCTGAGGACACGGC-3'; MBP-176(-), 5'-AGCTCGTTCAACATTGTTCTGGATCGC-3'; MBP-260(+), 5'-GCTCTAGACTCTAGGCCTCGTACA-3'; MBP+9(-), 5'-CCGCTCGAGCGGATGGTCTGAAGCTCGT-3'. The following primers were used for the MBP/METRE construct: p1, 5'-GGACGTTCGGGTTAGGGGAGGACACGGCGGTGACA-3'; p2, 5'-CCCTAACCCCAACGTCCTCTGGATCGCATCTGCCT-3'; p3, 5'-AACTGCAGGTCGACTCTAGAAGGCCTCGTACAGGC-3'; p4, 5'-AATGGCGAGGATCCCTCGAGTGAAGCTCGTCGGAC-3'.

MBPTRE/TATA and METRE/TATA reporter genes were obtained by cloning the corresponding MBPTRE or METRE double-stranded oligonucleotides upstream of the -33/+3 promoter sequence of the MBP gene, into the pBLCAT3 vector.

For the microinjection of Xenopus oocytes, the ME-315, MBP-256, and MBP-256/5'm were subcloned into pBluescript for single-stranded DNA preparations. The mycI(6-9)CAT plasmid was kindly provided by Georges Spohr (35). For in vitro transcription, the rat TRalpha 1 and human RXRalpha were subcloned into pSP64 (Promega). The human RXRalpha cDNA in which a Kozak sequence was introduced (36), as well as the rat TRalpha 1 and TRbeta 1 cDNAs were subcloned into pSG5PL (gift of Dr Hélène Richard-Foy (37)). pCMVbeta gal is from Amersham Pharmacia Biotech. A cDNA clone encoding SRC-1 was kindly provided by Dr. Malcom Parker. Four regions of this SRC-1 cDNA (A, nucleotide positions 67-617; B, 617-1259; C, 1259-2330; and D, 2330-3391; numbering is according to the data for GenBankTM accession no. U40396) were fused to glutathione S-transferase (GST) into pGEX vectors (Amersham Pharmacia Biotech). The N-CoR interaction domain (25) was cloned by reverse transcription-PCR using mouse liver total RNA as template. The cDNA obtained by reverse transcription using an oligo(dT) was amplified by PCR with the EcoRI end primers N-CoR (+6715), 5'-GGAATTCCCTACTTGCCTTCATTCTTCAC-3', and N-CoR (-7618), 5'-GGAATTCCCCATCATTTCTTCCTCATCCA-3' and was subcloned into the EcoRI site of the pGEX2T vector (Amersham Pharmacia Biotech).

Transfections-- NIH3T3 cells were maintained in culture and transiently transfected by electroporation as described previously (32). Briefly, each cuvette contained 4 × 106 cells at a density of 12.5 × 106 cells/ml and a total of 70 µg of plasmid DNA (30 µg of CAT reporter plasmid, 12 µg of each expression vector (or as indicated in the figure legends), 1 µg of pCMVbeta gal as internal control for transfection efficiency, and pUC19 to complete to 70 µg of transfected DNA). After electroporation, cells were distributed in four 60-mm dishes containing the transfection medium supplemented with 100 nM T3 or with vehicle alone. After 48 h, cell extracts were prepared and beta -galactosidase and CAT activities were determined as described previously (32).

Electrophoretic Mobility Shift Assays-- Proteins for electrophoretic mobility shift assays (EMSA) were obtained either by in vitro transcription and translation using the rabbit reticulocyte lysate system (Promega) or from Xenopus oocytes whole cell extracts prepared as described below. RXRbeta was prepared from nuclear extract of Sf9 cells infected with a recombinant baculovirus overexpressing mouse RXRbeta as described (38). The fusion proteins GST-N-CoR and GST-SRC were expressed in Escherichia coli and purified as described by the manufacturer (pGEX vectors; Amersham Pharmacia Biotech). The probes used correspond to the double-stranded oligonucleotides indicated in the figures flanked on their 5' side and 3' side by BamHI and HindIII sequence, respectively, and labeled with [alpha -32P]dATP.

For the binding reaction, the proteins were preincubated for 15 min at room temperature, in a buffer containing 25 mM Hepes, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 10% glycerol, 40 mM KCl, 1 mM dithiothreitol, and 8 µg of salmon sperm DNA in a total volume of 20 µl. After a further 15-min incubation at room temperature in the presence of 30,000 cpm of labeled probe, the complexes were separated on a 6% native polyacrylamide gel. For DNA binding competition experiments, a 1.25-12.5-fold molar excess (as indicated) of the unlabeled double-stranded competitor oligonucleotide was added for further 10 min after the incubation reaction. For kinetic experiments, a 50-fold molar excess of unlabeled competitor oligonucleotide was added after the incubation reaction and left for different time periods, as indicated in the figures. Scanning and treatment of the autoradiographies were performed using the Cirrus 1.2 software. When appropriate, gels were analyzed by densitometry.

Microinjection of Xenopus Oocytes-- The preparation of Xenopus stage VI oocytes and the microinjection procedure were essentially as described in Wong et al. (39) using the Nanoliter Injector (A203XVZ, World Precision Instruments, Inc.). The rTRalpha 1 (3 ng/oocyte) and human RXRalpha (3 ng/oocyte) mRNAs were injected into the cytoplasms of oocytes, which were incubated at 18 °C overnight in MBSH buffer (10 mM Hepes, pH 7.6, 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM MgSO4, 0.41 mM CaCl2, 0.33 mM Ca(NO3)2) supplemented with antibiotics (50 units/ml of ampicillin and streptomycin). Then the ME-315, MBP-256, or MBP-256/5'm single-stranded reporter genes were microinjected into oocyte nuclei (1 ng/oocyte) with the internal control mycI(6-9)CAT (0.2 ng/oocyte) as indicated in the legend of Fig. 6. The oocytes were incubated in MBSH buffer supplemented with antibiotics during 6 h and then collected for transcription analysis (see below). For EMSA, 10 oocytes were injected, and after an overnight incubation, whole cell extracts were prepared as described previously (39).

Primer Extension Analysis-- A group of 15-20 oocytes was collected per sample and homogenized in 10 µl/oocyte of 0.25 M Tris-HCl at pH 8.0. The equivalent of 10 oocytes was used for RNA purification and transcription analysis. Total RNA was prepared from the homogenate using the RNazolTM method (Tel-Test Inc.) as described by Wong et al. (39). Half of the RNA sample (5 oocytes) was analyzed by primer extension.

The RNA (10 µl) was supplemented with 10 µl of a first strand synthesis buffer (2×, provided by Life Technologies, Inc.), 5 mM dithiothreitol, and end-labeled CAT (5'-GGT GGT ATA TCC AGT GAT TTT TTT CTC CAT-3') and H4 (5'-GGC TTG GTG ATG CCC TGG ATG TTA TCC-3') primers (0.2 pmol each). The H4 primer, used as an internal control, detects the endogenous histone H4 mRNA. Annealing occurred for 10 min at 65 °C, 30 min at 55 °C, 20 min at 37 °C, and 5 min at room temperature. The reverse transcription reaction was carried out at 42 °C upon the addition of 1 µl of 10 mM dNTPs and 100 units of the SuperscriptTMII RT (Life Technologies, Inc.). The reaction was stopped after 1 h by ethanol precipitation. The extension products were resolved on a 8% sequencing gel, visualized by autoradiography, and quantitated by densitometry. CAT mRNA levels corresponding to ME-315, MBP-256, or MBP-256/5'm reporter were standardized to the endogenous histone H4 mRNA levels.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The ME and MBP Genes Are Differentially Transactivated by TRalpha 1 and TRbeta 1-- To detect functional differences between the two main TR subtypes in the regulation of the ME and MBP promoters, we used transfection experiments in NIH3T3 cells. These cells express RXR as most cell lines do but have very low TR mRNA levels (data not shown). The two CAT reporter constructs used contain either the promoter region of the ME gene up to -315 (ME-315), which encompasses the TRE between -287 and -260 (32) or the MBP promoter up to position -256 (MBP-256) including the TRE located between positions -195 and -165 (31) (Fig. 1A). The T3-mediated response of the ME-315 reporter gene increased with the amounts of cotransfected expression plasmids for TRalpha 1 or TRbeta 1 (Fig. 1B). However, repression by the unliganded TRalpha 1 (mean value of 58% of repression when the cells were transfected with 3 µg of expression plasmid, p < 0.05) was more important than in the presence of TRbeta 1 (mean value of 73% for the corresponding point, statistically not significant). The overall T3-induced response was also more potent with TRalpha 1 than with TRbeta 1, a difference that cannot be attributed to TRalpha 1 and TRbeta 1 differences in expression levels (see below). As seen in Fig. 1C, the MBP-256 reporter gene poorly responded to T3 and TRalpha 1, and this response was not improved by transfection of higher amounts of TR expression vector. In contrast, TRbeta 1-mediated activity was dose-dependent, leading to a significant difference in T3 response between the two TR subtypes. Because of the opposite results obtained when using the ME and the MBP reporter genes, we can rule out an apparent functional difference that would be due to a difference in the level of receptor expression. This was further assessed by a RNase protection assay that showed that the level of TRalpha 1 and TRbeta 1 mRNA after transfection were similar (data not shown). Moreover, the same pattern of activation and repression was observed using different vectors for expressing TRs (pRSV instead of pSG5PL; data not shown). Thus, in transfected NIH3T3 cells, TRalpha 1 induces a strong T3 response of ME-315 but a weak activation of MBP-256. In contrast, TRbeta 1 mediates an efficient T3 stimulation of both ME and MBP reporter genes.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Differential transactivation properties of TRs. A, schematic representation of the CAT reporter genes. The respective positions and sequences of the METRE, organized as a direct repeat (DR4), and MBPTRE, organized as an inverted palindrome (IP6), are given within their wild type promoter context (ME-315, MBP-256). B, comparison of the T3 response mediated by TRalpha 1 (filled bars) and TRbeta 1 (striped bars) using the ME-315 reporter construct. NIH3T3 cells were cotransfected with the reporter construct (7.5 µg/dish) and increasing amounts of pSG5TRalpha 1 or pSG5TRbeta 1 in the presence (+) or absence (-) of 100 nM T3 as indicated. The total amount of expression plasmid was adjusted to 3 µg with the empty vector pSG5. A pCMVbeta (0.25 µg/dish) was included as an internal control. CAT activity levels were standardized to beta -galactosidase expression. The basal activity of the reporter plasmid in the absence of receptor and T3 was set to 1. Results are the mean ± S.E. of at least three independent experiments. Statistical analyses show that the repression by the unliganded TRalpha 1 is significant (Student's t test value, p = 0.02) in contrast to that mediated by TRbeta 1. The overall difference of the T3 response mediated by TRalpha 1 and TRbeta 1 is also significant (p < 0.05). C, comparison of the T3 response mediated by TRalpha 1 (filled bars) and TRbeta 1 (stripped bars) using MBP-256. The experimental conditions used are as described in B. The difference in the T3 response mediated by TRalpha 1 and TRbeta 1 is significant at 1.5 and 3 µg of expression plasmid (Student's t test value, p < 0.01). D, effect of the TRE structure in the T3 response mediated by TRs. Transfection in NIH3T3 cells of MBP-256 or MBP/METRE CAT reporter genes with pSG5, pSG5TRalpha 1, and pSG5TRbeta 1 (3 µg/dish), as described for B is shown. Both MBPTRE/TATA and METRE/TATA CAT reporter genes were cotransfected in NIH3T3 cells with pSG5 or pSG5TRalpha 1 (3 µg/dish).

Role of the TRE Structure in the Transactivation Potency of TRalpha 1 and TRbeta 1-- One distinct feature of the ME and MBP promoter that may participate in their different patterns of regulation by T3 concerns the TRE structure, which corresponds to a DR4 in the ME promoter and to an inverted palindrome with a 6-base pair spacing (IP6) in the MBP promoter (Fig. 1A). To evaluate whether the nature of the TRE was responsible of the poor TRalpha 1-mediated T3 responsiveness of the MBP promoter, we changed the MBPTRE for METRE within the context of the MBP promoter (MBP/METRE; Fig. 1A). As seen in Fig. 1D, TRbeta 1 mediated a similar T3 responsiveness of the wild type and mutated promoter, in contrast to TRalpha 1, which was significantly more efficient when the METRE replaces the MBPTRE. A distinct role of these two TREs in the potency of TRalpha 1-mediated transcriptional activation was further analyzed in the context of a common minimal promoter that only contains the TATA region from -33 to +3 of the MBP promoter (MBPTRE/TATA and METRE/TATA). In this context again, the MBPTRE solely conveyed a low activation by TRalpha 1 as compared with that mediated by METRE (5-fold versus 15-fold, respectively). We thus can conclude that in these different promoter contexts, the MBPTRE element is by itself responsible of the poor TRalpha 1-mediated response of the MBP promoter, while it mediates efficient regulation by TRbeta 1.

Binding Pattern of TRalpha 1 and TRbeta 1 on METRE and MBPTRE-- To evaluate whether the specific pattern of T3 response through particular response elements by TRalpha 1 may reflect differences in DNA binding properties of the TR subtypes, EMSAs were performed with labeled double-stranded oligonucleotides corresponding to the two TREs. Neither TRalpha 1 nor TRbeta 1 was able to bind to the ME probe in absence of RXR. The addition of RXR to the TRs resulted in the formation of a major complex that corresponds to the TR/RXR heterodimer (Fig. 2A). The absence or presence of T3 in the reaction did not change the strength of this signal (data not shown). Binding of TRs to the MBPTRE was quite different from this pattern. In absence of RXR, TRalpha 1 formed two complexes: a fast migrating complex that corresponds to a TRalpha 1 monomer and a slower complex corresponding to a TRalpha 1 homodimer (Fig. 2B). The addition of T3 triggered the disappearance of the upper complex (Fig. 2B, compare lanes 3 and 4) while provoking a small but reproducible downshift of the faster migrating complex, consistent with their identification as TR homodimer and monomer, respectively (22-24). Increasing amounts of TRalpha 1 resulted in a parallel increase of the intensity of both the monomer and the homodimer bands (Fig. 2B, lanes 7-9), indicating the absence of cooperativity for the formation of the homodimer. In the presence of both TRalpha 1 and RXR, a third complex was detected. This complex corresponds to a TRalpha 1/RXR heterodimer and was not disrupted by T3 (Fig. 2B, lanes 5 and 6). As seen in Fig. 2C, TRbeta 1 was also able to form a retarded complex on the MBPTRE in absence of RXR. Its slow migration and T3-induced disruption identified it as a TRbeta 1 homodimer (Fig. 2C, lanes 1 and 2). No complex corresponding to a TRbeta 1 monomer was observed (Fig. 2C, lanes 5-7), although trace amounts were occasionally detected in presence of high concentrations of TRbeta 1. In the presence of RXR, TRbeta 1/RXR heterodimers were formed and showed a slightly increased mobility in presence of T3 (Fig. 2C, lanes 3 and 4). The addition of more RXR to TRalpha 1 or TRbeta 1-containing binding reactions with the MBPTRE probe resulted in the exclusive detection of TRalpha 1/RXR or TRbeta 1/RXR complexes (data not shown). In summary, TRalpha 1/RXR and TRbeta 1/RXR complexes form with a similar efficiency on both TREs. However, a striking difference resides in the binding of TRalpha 1 monomers and TRbeta 1 homodimers to the MBPTRE, whereas such complexes are not seen on the METRE.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Distinct in vitro binding pattern of TRs to the METRE and MBPTRE. EMSAs using in vitro translated TRalpha 1 or TRbeta 1 in the presence or absence of Sf9-expressed recombinant RXR and of 100 nM T3 as indicated were incubated with a radiolabeled oligonucleotide encompassing the METRE sequence (A) or the MBPTRE sequence (B and C). In B, lanes 7-9, increasing amounts of in vitro translated TRalpha 1 (6, 15, and 30 fmol, respectively) show the noncooperative binding of TRalpha 1 monomers in the absence of RXR. In C, lanes 5-7, increasing amounts of in vitro translated TRbeta 1 (6, 15, and 30 fmol, respectively) do not allow the detection of TRbeta 1 monomer. In all panels, TR indicates the monomer complex, TR/TR indicates the homodimer complex, and TR/RXR indicates the heterodimer complex.

We further characterized the properties of the TRalpha 1-containing complexes bound to MBPTRE by competition experiments in EMSA. In such experiments, unlabeled DNA response elements compete with the labeled probe for TR binding, allowing the measurement of either the affinity or the off-rate of the TRalpha 1/MBPTRE complex depending on the experimental design. At equilibrium, a 4-fold molar excess of cold competitor led to a 50% decrease in hetero- and homodimer complexes, while more than 10-fold molar excess was required for a similar inhibition of the monomer complex (Fig. 3A). This result indicates that the affinity of TRalpha 1 monomer binding is lower than that of dimer binding. A kinetic study showed the disappearance of the complexes as a function of time in presence of a 50-fold molar excess of the competitor. Most of the monomer and most of the homodimer complexes disappeared within the first minute, while 3 min were needed to reduce the heterodimer complex to only 50% (Fig. 3B). This result suggests that the off-rate of TRalpha 1 monomer and homodimer from MBPTRE is higher than that of the TRalpha 1/RXR heterodimer.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Competition and kinetic DNA binding studies of TRalpha 1 monomers, homodimers, and heterodimers. EMSAs using in vitro translated TRalpha 1 incubated with the radiolabeled MBPTRE probe were performed in the presence of Sf9-expressed recombinant RXR so that the three complexes (monomer, homodimer, and heterodimer) could be observed. A, after 15 min of incubation, competitions were performed during 10 min in the absence of or with a 1.25-, 2.5-, 5-, and 12.5-fold molar excess of unlabeled MBPTRE (lanes 1-5, respectively). B, after 15 min of incubation, a 50-fold molar excess of unlabeled MBPTRE was added to the reaction, which was stopped after 0, 1, 3, 5, and 10 min (lanes 1-5, respectively). The graphs on the left correspond to the densitometric analysis of the autoradiographs shown on the right.

Binding of TRalpha 1 as Monomer Requires a Specific Extended Half-site-- The occurrence of a high monomer binding efficiency that was TRE and TR subtype-specific prompted us to identify the corresponding sequence requirement present in MBPTRE. Mutation of the downstream half-site with respect to the orientation of the TRE in the wild-type promoter (MBP 3'm; Fig. 4A) completely abolished TRalpha 1 as well as TRbeta 1 binding in the absence and in the presence of RXR (Fig. 4B, lanes 5-8). In contrast, mutation of the 5' half-site (MBP 5'm; Fig. 4A) did not affect TRalpha 1 monomer binding, but neither TRalpha 1 nor TRbeta 1 homodimers could form (Fig. 4B, lanes 9 and 11). These results further excluded the possibility that the complex migrating as homodimer corresponds to the independent and adjacent binding of two TR molecules. However, most unexpectedly, TRalpha 1/RXR and TRbeta 1/RXR did bind to MBP 5'm although to a lesser extent than to the wild type MBPTRE (Fig. 4B, compare lanes 10 and 12 with lanes 2 and 4). The same results were obtained when the mutation introduced in the 5' half-site consisted of random nucleotides (Fig. 4B, compare MBP 5'm lanes 9-12 with MBP 5'm/N lanes 13-16). This ruled out a possible artifact due to the nature of the mutations and clearly demonstrated that the TRalpha 1 monomer specifically binds to the 3' half-site. The importance of the three nucleotides flanking the AGGACA core hexamer of this half-site in 5' was then assessed by mutating them within the full-length MBPTRE (MBP agt, Fig. 4A). These mutations abolished detectable monomer binding and thus demonstrated that the nonanucleotide CTGAGGACA is required in the wild-type MBPTRE for TRalpha 1 monomer binding (Fig. 4B, lanes 17-20). Moreover, the formation of TR/RXR heterodimer complexes onto MBP agt dramatically decreased, indicating that heterodimers also make specific contacts with these nucleotides. In summary, these mutagenesis experiments demonstrated that (i) only the 3' extended half-site of MBPTRE is capable of binding the TRalpha 1 monomer and (ii) this specific half-site also strongly participates in the binding of TR/RXR heterodimer.


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 4.   Specific binding of TRs on the 3' half-site of MBPTRE. A, sequences of wild type and mutated MBPTRE. The arrows underline hexameric half-sites, and regions enclosed in shaded boxes correspond to mutated sequences. B, EMSAs using in vitro translated TRalpha 1 and TRbeta 1 incubated in the presence or absence of Sf9-expressed recombinant RXR, as indicated. The radiolabeled probes are as indicated below each panel. For comparison, lanes 1-4 correspond to the observed complexes bound onto the wild type TRE, run with the same extracts and on the same gel as lanes 9-12. In lanes 2 and 4, heterodimers appear as a doublet, whose fainter and faster migrating complex is composed of TR and a protein from Sf9 extract, most likely USP (72).

Analyses of the Transcriptional Activity of TRalpha 1 Monomer-- In a first set of experiments, we introduced the mutation corresponding to MBP 5'm into the wild-type MBP promoter, creating MBP-256/5'm, and used this reporter gene in transfection assay of NIH3T3 cells. This reporter gene bearing only a half-site TRE exhibited a weak but significant response to T3 (Fig. 5). The T3 response by both TRalpha 1 and TRbeta 1 was affected by the mutations and corresponded to the reduction of the efficiency of the TR/RXR heterodimer binding onto MBP 5'm (see Fig. 4B). Thus, the correlation between the intensity of heterodimer binding and the transactivation level suggested that, in transfected cells, the binding of heterodimers onto the half-site rather than the monomer formation, which was not affected by the mutation, may account for the residual response.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5.   Functional analyses of the TRalpha 1 monomer binding site. NIH3T3 cells were cotransfected with the wild type MBP-256 or with the mutation MBP-256/5'm reporter plasmid. pSG5, pSG5TRalpha 1, and pSG5TRbeta 1 (3 µg/dish) were cotransfected in the presence or absence of 100 nM T3 as indicated. pCMVbeta (0.25 µg/dish) was included as an internal control. CAT activity levels were standardized to beta -galactosidase expression. The basal activity of the reporter plasmid in the absence of receptor and T3 was set to 1. Results are the mean ± S.E. of three independent experiments.

To assess the respective roles of TRalpha 1 monomer and TRalpha 1/RXR heterodimer in TRalpha 1-mediated T3 response, we analyzed the transactivation properties of TRalpha 1 and TRbeta 1 in Xenopus oocytes, since they do not express detectable amounts of TR and RXR proteins (39). Oocytes from stages VI were injected with TR mRNA alone or with RXR mRNA. The corresponding oocyte extracts were then used in an EMSA, yielding similar binding patterns as those observed with TR expressed in reticulocyte lysate. As expected, when using the MBPTRE as probe, TRalpha 1 formed mainly monomer and TRbeta 1 homodimer, whereas heterodimer formation was only seen upon coinjection of RXR mRNA (Fig. 6A). Surprisingly in this model, unliganded TRalpha 1 or TRbeta 1 in absence of RXR mediates a strong repression of MBP-256 reporter gene as measured by primer extension of the RNA transcripts. The addition of T3 relieved this repression and further enhanced the CAT gene expression above the basal level. This T3 effect was slightly reinforced upon co-injection of RXR mRNA (Fig. 6B and 6B'). The same pattern of regulation was observed when using the MBP-256/5'm vector, to which TRalpha 1 monomer binds efficiently, whereas TR/RXR binds with a lower affinity (see Figs. 4B and 6C). The fact that TRbeta 1 cannot bind to MBP-256 as a monomer nor to MBP-256/5'm as a homodimer suggested that neither of these complexes could explain the TR activity in the absence of RXR. We thus further analyzed the regulation of the ME reporter gene onto which only heterodimer could be observed. Again, unliganded TRalpha 1 and TRbeta 1 in the absence of RXR caused a repression, while the addition of T3 to these oocytes led to an activation of the ME reporter gene. Further addition of RXR improved the T3-mediated induction (Fig. 6D). The reporter mycI(6-9)CAT vector used as a control was not responsive to the presence or the absence of receptors and/or T3 (data not shown).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 6.   TRalpha 1 and TRbeta 1 expressed in Xenopus oocytes mediates a T3 response. A, in vitro transcribed mRNAs (lanes 1-12) corresponding to TRalpha 1 or TRbeta 1 and/or human RXRalpha were injected into Xenopus oocyte cytoplasm (mRNA). Whole cell extracts were prepared as described under "Materials and Methods" and analyzed by EMSA with the radiolabeled MBPTRE probe (lanes 1-6) and the MBP5'm probe (lanes 7-12). B, B', C, and D, Xenopus oocytes were microinjected into the cytoplasm with TRalpha 1 mRNA (3 ng/oocyte), TRbeta 1 mRNA (3 ng/oocyte), with or without RXRbeta mRNA (3 ng/oocyte) as indicated at the top of each panel. After an overnight incubation, nuclei were microinjected with MBP-256 (B, B'), MBP-256/5'm (C), or ME-315 (D) CAT reporter genes (1 ng of single-stranded DNA/oocyte). Oocytes were further incubated 24 h in the presence (+) or absence (-) of 100 nM T3. Primer extension analyses of total RNA from 10 oocytes/sample were performed with a radiolabeled CAT primer for the reporter gene activities together with the H4 primer as internal control.

Thus, in the mammalian NIH3T3 cells, a correlation could be made between the low efficiency of TR binding as a heterodimer on an extended half-site TRE and the weak T3 response it mediates. However, a transcriptional activity of the DNA-bound TRalpha 1 monomer in mammalian cells could not be completely excluded based on these experiments. In contrast, in Xenopus oocytes, TRalpha 1 and TRbeta 1 can repress reporter gene expression in the absence of T3 and induce it in the presence of T3, regardless of whether RXR mRNA is co-injected. These activities do not correlate with the ability to form monomer or homodimer, raising the hypothesis that some Xenopus oocyte-specific nuclear factors are participating as partners of TRalpha 1 and TRbeta 1 in this experimental model.

The TRalpha 1 Monomer Interacts Neither with N-CoR Nor with SRC-1-- The interaction of TR with co-repressors such as N-CoR or SMRT was shown to participate in the transcriptional repression mediated by TR in the absence of its ligand (25, 26), while the co-activator SRC-1 plays a role in the positive enhancement of gene expression mediated by liganded TR (27). Both factors are present in NIH3T3 cells and thus should be involved in TRalpha 1 monomer activity, if there is any. Using EMSAs, we thus assessed the specific interacting properties of DNA-bound TRalpha 1 complexes with these co-factors. Because the high molecular weight of N-CoR and SRC-1 precluded their use as full-length proteins in EMSA, we expressed the mouse N-CoR domain known to interact with nuclear receptors (25) as a GST fusion protein (Fig. 7A). Interestingly, as shown in Fig. 7, TRalpha 1 bound as a monomer on MBPTRE as well as on MBP 5'm was not able to bind N-CoR, since no supershift was observed (Fig. 7B, lanes 1-7). In contrast, the DNA-bound TR/RXR heterodimer was supershifted in the presence of N-CoR, due to the formation of a ternary complex. T3 addition led to the disruption of this higher order complex and to the reappearance of the heterodimer (Fig. 7B, lanes 8-10).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 7.   TRalpha 1 monomer bound to MBPTRE does not interact with N-CoR. A, schematic representation of the murine N-CoR cDNA. Two amino-terminal repressing domains (RDI, nucleotides 117-1053; RDII, nucleotides 2373-3165) are represented by shaded boxes, and the C-terminal interacting domain is shown by a black box (ID, nucleotides 6834-7017). The N-CoR region from nucleotide 6715 to 7618, encompassing the interaction domain with TR, was subcloned into the pGEX2T vector. The GST fusion protein was expressed in E. coli and used in EMSA. B, EMSAs using in vitro translated TRalpha 1 incubated in the presence or absence of GST-N-CoR (1 µg of partially purified protein), 100 nM T3, and Sf9-expressed recombinant RXR as indicated. The radiolabeled probe was MBPTRE (lanes 1-3 and 8-10) or MBP 5'm (lanes 4-7). A specific interaction of DNA-bound TR/RXR with N-CoR is released by T3, which also provoked a small downshift of the TR/RXR complex.

To analyze the interaction of SRC-1 with TR complexes bound to DNA, we first subcloned consecutive regions (arbitrarily called A, B, C, and D) of the SRC-1 cDNA into an expression vector. We then tested the different domains for their interaction with the TRalpha 1/RXR heterodimer (see Fig. 8A). The region B from amino acid 188 to 401, according to the human SRC-1 sequence (27), showed a T3-dependent interaction with the DNA-bound heterodimer, while the three other regions, A, C, and D, did not (Fig. 8B, lanes 1-5 and data not shown). Interestingly, the monomer bound to MBPTRE or MBP 5'm was unable to form a complex with the SRC-1 B region in the absence or presence of T3 (Fig. 8B, lanes 6-10). The small reduction in the monomer band intensity in presence of T3 might reflect the TRalpha 1/SRC-1 interaction occurring in solution.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 8.   TRalpha 1 monomer bound to MBPTRE does not interact with SRC-1. A, schematic representation of the SRC-1 cDNA. The different regions of the SRC-1 cDNA (A, nucleotides 67-617; B, nucleotides 617-1259; C, nucleotides 1259-2330; D, nucleotides 2330-3391) were subcloned into the pGEX 5 × 3 vector. The GST fusion proteins were expressed in E. coli and used in EMSA. B, EMSAs using in vitro translated TRalpha 1 incubated in the presence or absence of GST-SRC-1 clone A or clone B (1 µg of partially purified protein) in the presence or absence of 100 nM T3 and RXR, as indicated. The radiolabeled probes were MBPTRE (lanes 1-8) or MBP 5'm (lanes 9-10).

In summary, while the TR interactions with co-factors in solution are well documented, we demonstrated herein that the DNA-bound TRalpha 1 monomer is unable to interact either with N-CoR or with SRC-1, thereby providing a molecular explanation for the weak, if existent, transcriptional regulatory properties (repression or activation) of the TRalpha 1 monomer in mammalian cells.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this study, we report on the differential regulation of the MBP promoter by TRalpha 1 and TRbeta 1 in mammalian cells. We show that the weakness of the T3 response mediated by TRalpha 1 correlates with its ability to form monomers on the MBPTRE. This TRalpha 1 monomer interacts neither with the N-CoR nor with the SRC-1 domains known to interact with the receptor. These functional characteristics may have profound implications with respect to the T3 regulation of the MBP gene during development.

Binding of TR Monomer Has Specific Sequence Requirements-- Binding of TR as a monomer was first described using the synthetic TREpal as probe (40). Later, the observation that nucleotides flanking the core hexamer might affect TRE activity (41) was at the basis of an unbiased search for an optimal DNA binding sequence for TRalpha 1 monomer, which resulted in the octameric sequence 5'-TAAGGTCA (42). Further work with diverse synthetic octameric sequences determined the 5'-(T/C)(A/G)AGGTCA-3' motif as consensus half-site for the TRalpha 1 monomer (43). Among the natural elements, the rat growth hormone, the chick lysozyme, and the rat alpha - and beta -myosin heavy chain genes also contain positive TREs comprising an optimal or suboptimal octamer sequence to which TR binds as monomer (23, 44-49). In the natural elements that we analyzed, the MBPTRE sequence contains the nonamer CTGAGGACA whose disruption in the 5' part or in the core sequence results in the loss of TRalpha 1 monomer binding (see Fig. 4B). In contrast, the sequence of the two half-sites that composes the METRE and taken as nonamers are TTGGGGTTA and GGGAGGACA. None of them can bind TRalpha 1 monomer in the conditions used in the present work, indicating that TRalpha 1 monomer binding has strict requirements covering at least 8 or 9 nucleotides. Some reports, however, indicated that purified E. coli-expressed TR may bind as a monomer to METRE (44, 45, 48). Two nonexclusive hypotheses can explain the apparent discrepancies with our own work. First, the amount of TR expressed in E. coli may be much higher than that obtained in reticulocyte lysate, allowing the detection of low affinity complexes. Second, post-translational modifications that do not occur in E. coli could be important for TR binding properties (50) as shown for c-erbAalpha 2, which binds as monomer only after mutation of two phosphorylation sites (51).

TR/RXR Can Bind an Extended Half-site-- Surprisingly, the nonamer present in the MBPTRE, to which TRalpha 1 monomer binds, also allowed the formation of TR/RXR heterodimer but not of TR/TR homodimer complexes (see Fig. 4B). This suggests that, since TR and RXR heterodimerize in solution (13), the strong and specific anchorage of TR onto its half-site allows weaker or nonspecific DNA contacts by RXR. This is indeed substantiated by methylation interference assays, which showed that RXR contacts the 5' half-site of a DR4 with rather weak bonds, as compared with those of TR with the 3' half-site (52, 53). This ability of a heterodimer to bind to an extended half-site may also explain some unexpected observations of TR/RXR binding to direct repeats elements with a variety of spacing lengths between the half-sites (54, 55). This is reminiscent of the RXR/Nurr1 heterodimer, which can trigger a 9-cis-retinoic acid responsiveness through an 8-base pair monovalent site (56). Activation by TR through an octamer element has been previously reported and was attributed to the monomer activity (57). Herein, we demonstrated that TR/RXR heterodimers are probably responsible for the extended half-site activity that we detected.

DNA-bound TR Monomer Does Not Interact with NCoR or SRC-1-- Recent studies on the mechanism of action of nuclear receptors identified factors with which they interact (58). More precisely, two co-repressors N-CoR and SMRT interact with the unliganded TR, while TR interaction with the co-activators SRC-1 and p300/CBP is T3-dependent (25, 26, 28, 59, 60). These interactions were characterized using yeast two-hybrid systems or pull-down assays and showed that TR or TR/RXR interacted with these co-factors in solution. Herein, we demonstrated by EMSA that TR monomer bound to MBPTRE interacts neither with GST-N-CoR nor with GST-SRC-1. The DNA-bound heterodimer, in contrast, forms a ternary complex with N-CoR in the absence of T3 (herein and Ref. 25) and interacts with SRC-1 in presence of T3. While this manuscript was in preparation, Zamir et al. (61) also showed that DNA-bound TR monomer does not interact with GST-NCoR.

Two distinct domains of TR mediate the interaction with these two co-factors. N-CoR interacts with the hinge region of TR (62, 63), while a mutation in the helix 3 or in the helix 12 of the ligand binding domain impaired the interaction with SRC-1 (64, 65). Whether the TR molecule is in solution or bound to DNA as a monomer may modify the accessibility of these interacting domains. Since SRC-1 can contact both TR and RXR, it is also possible that a co-activator may need to be in contact with two molecules in order to stabilize the interaction. Alternatively, RXR may induce a conformational transition on TR, affecting its interaction with SRC-1. In any case, the absence of interaction of the TRalpha 1 monomer with the co-factors tested provides a mechanistic explanation for the lack of TRalpha 1 monomer transcriptional activity.

Functional and Structural Differences of TRalpha 1 and TRbeta 1-- So far, all T3-responsive genes analyzed in transfections exhibit an equal or slightly better responsiveness to TRalpha 1 than to TRbeta 1 as emphasized herein with the ME gene. Besides a T3-independent TRbeta 1-specific activation of the pcp-2 gene (66), the MBP promoter is the first example of a clear contrast between TRalpha 1- and TRbeta 1-mediated T3 responsiveness. In parallel, previous EMSAs performed on various synthetic and natural elements indicated that TRbeta 1 more readily homodimerizes than TRalpha 1 and that TRalpha 1 binds more easily as monomer than TRbeta 1 (23, 40, 44, 46, 67). In this respect, the binding pattern of TRalpha 1 and TRbeta 1 to the MBPTRE is paradigmatic.

The ability of binding as a monomer is mostly a property of orphan nuclear receptors (19), and the structural determinants involved in monomer binding were particularly well analyzed for the orphan receptor NGFI-B. Binding of NGFI-B to an extended half-site involves the A and T boxes of the receptor, located in the hinge region (68). In TR, a long alpha -helix in this region that interacts with the minor groove of the half-site and with its flanking sequence (69) may participate in DNA contacts required for binding of TR as monomer. Little difference in the A and T boxes is seen between TRalpha 1 and TRbeta 1. However, the C-terminal part of the hinge domain is more divergent and may play a role in the differences seen in binding patterns. In parallel, dimerization determinants are found in the TR ligand binding domain as well as in the DNA binding domain (10). Detailed comparative analyses of the structural differences within these domains in TRalpha 1 and TRbeta 1, using the MBPTRE as the DNA partner would help to precisely identify the TR determinants for monomer and homodimer formation. They may also give a tool for understanding the homodimer function, which remains elusive.

Transcriptional Regulatory Patterns Mediated by TR Differ in NIH3T3 Cells and in Xenopus Oocytes-- Xenopus oocytes provide a model in which RXR has not been detected (39). The results we obtained in this model are surprising. First, without co-injecting RXR mRNA and in the absence of T3, both TR isotypes led to a strong repression of reporter genes carrying various TREs: an IP6, a half-site, or a DR4. That a TR monomer could be responsible for such an activity was not supported by the fact that TRbeta 1 onto MBPTRE and TRalpha 1 or TRbeta 1 onto the METRE could not form monomer. The same reasoning applies to the involvement of homodimers that were exclusively seen with the MBP-256. Second, in this model, no differences between TRalpha 1 and TRbeta 1 were observed. One hypothesis would be that, in oocytes, TR irrespective of the complex that it forms on DNA is able to recruit partners possibly different from those known in mammalian cells. They are unlikely to be RXR homologues, since no RXR-like activity was detected in the oocyte extracts obtained after TR mRNA injection (Fig. 6A; see also Ref. 39). Little is known yet about the co-repressors and co-activators that are present in Xenopus oocytes. Their analysis could be highly valuable to understand the TR mechanism of action in these cells.

TRalpha 1 and TRbeta 1 in the Regulation of the MBP Gene during Brain Development-- In rat embryos from E14 onwards, TRalpha 1 mRNA is detectable at high levels during all developmental stages of the brain, whereas TRbeta 1 mRNA is low or undetectable. The insensitivity of MBP to T3 regulation at that time suggests that TRalpha 1 may indeed occupy the MBPTRE sequence as monomer during development. After birth, TRbeta 1 mRNA expression peaks during the first 3 weeks (2, 7, 8). This correlates with high myelinating activity and high T3-dependent MBP expression. Our experiments suggest that after birth, the nonproductive promoter occupancy by TRalpha 1 monomer is challenged by the rise in TRbeta 1 concentration. In this model, the relative intracellular concentration of TR and RXR is an important determinant of the hormonal response as kinetic studies emphasize the higher affinity and better stability of the TR/RXR heterodimer complex versus homodimer and monomer (herein and Refs. 40 and 54). Three RXR isotypes are expressed in mammals, and all are able to form heterodimers with TR (18). RXRbeta and RXRgamma transcripts have been detected by in situ hybridization in the central nervous system of the mouse embryo from day 10.5 onwards and in the adult (18, 70). Thus, both TRs and RXRs are present during the myelination period; however, their relative levels are not known. It must also be kept in mind that the interaction of TRs with the MBPTRE in neural tissue may involve other tissue-specific factors in addition to RXR, which might result in a transactivation pattern different from that we have observed in NIH3T3 cells. In view of the rather high level of TRalpha 1 expression in the developing brain, associated with the high efficiency with which TRalpha 1 monomers bind to the MBPTRE, the physiological relevance of TRalpha 1 monomers deserves further consideration.

In conclusion, our results reveal a new TR mode of action, which is specific to TRalpha 1 monomers, which bind to a monovalent site present in otherwise functional TREs. This pathway may play an important role in modulating T3 effects at different stages of development when TRalpha 1 and RXR expression varies. At the molecular level, this study first emphasizes the stringent DNA sequence requirement for TRalpha 1 monomer binding in vitro. It also stresses the importance of carefully assessing the interaction of co-factor/receptor in the context of DNA-bound complexes, which may differ from interactions in solution. Altogether, our results strengthen the hypothesis that DNA, i.e. the TREs herein, exert an allosteric control of the transcriptional activities of nuclear receptors (71).

    ACKNOWLEDGEMENTS

We thank W. Wahli for helpful discussions during the preparation of the manuscript and O. Hagenbüchle and N. Mermod for reading it critically. We also thank M. Parker, H. Richard-Foy, and A. Hihi for the gift of SRC-1, pSG5-PL, and RXR-containing Sf9 cellular extracts, respectively, and J. Goudet for statistical analyses.

    FOOTNOTES

* This work was supported by the Etat de Vaud and the Swiss National Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Institut de Biologie Animale Bâtiment de Biologie, Université de Lausanne CH-1015 Lausanne, Switzerland. Tel.: 41 21 692 41 40; Fax: 41 21 692 41 15; E-mail: beatrice.desvergne{at}iba.unil.ch.

The abbreviations used are: TR, thyroid hormone receptor; TRE, thyroid hormone response element; T3, thyroid hormone; ME, malic enzyme; MBP, myelin basic protein; DR, direct repeat; IP, inverted palindrome; RXR, 9-cis-retinoic acid receptorCAT, chloramphenicol acetyltransferaseGST, glutathione S-transferaseEMSA, electrophoretic mobility shift assay.
    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Gronemeyer, H., and Laudet, V. (1995) Protein Profile 2, 1173-1308[Medline] [Order article via Infotrieve]
  2. Strait, K. A., Schwartz, H. L., Perez-Castillo, A., and Oppenheimer, J. H. (1990) J. Biol. Chem. 265, 10514-10521[Abstract/Free Full Text]
  3. Forrest, D., Sjöberg, M., and Vennström, B. (1990) EMBO J. 9, 1519-1528[Medline] [Order article via Infotrieve]
  4. Bradley, D. J., Young, W. S., III, and Weinberger, C. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7250-7254[Abstract/Free Full Text]
  5. Strait, K. A., Schwartz, H. L., Seybold, V. S., Ling, N. C., and Oppenheimer, J. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3887-3891[Abstract/Free Full Text]
  6. Forrest, D., Hallbook, F., Persson, H., and Vennström, B. (1991) EMBO J. 10, 269-275[Medline] [Order article via Infotrieve]
  7. Mellström, B., Naranjo, J. R., Santos, A., Gonzalez, A. M., and Bernal, J. (1991) Mol. Endocrinol. 5, 1339-1350[Abstract/Free Full Text]
  8. Bradley, D. J., Towle, H. C., and Young, I. W. S. (1992) J. Neurosci. 12, 2288-2302[Abstract]
  9. Bradley, D. J., Towle, H. C., and Young, W. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 439-443[Abstract/Free Full Text]
  10. Desvergne, B. (1994) Mol. Cell. Endocrinol. 100, 125-131[CrossRef][Medline] [Order article via Infotrieve]
  11. Yu, V. C., Delsert, C., Andersen, B., Holloway, J. M., Devary, O. V., Naar, A. M., Kim, S. Y., Boutin, J. M., Glass, C. K., and Rosenfeld, M. G. (1991) Cell 67, 1251-1266[CrossRef][Medline] [Order article via Infotrieve]
  12. Leid, M., Kastner, P., Lyons, R., Nakshatri, H., Saunders, M., Zacharewski, T., Chen, J. Y., Staub, A., Garnier, J. M., Mader, S., and Chambon, P. (1992) Cell 66, 377-395
  13. Marks, M. S., Hallenbeck, P. L., Nagata, T., Segars, J. H., Appella, E., Nikodem, V. M., and Ozato, K. (1992) EMBO J. 11, 1419-1435[Medline] [Order article via Infotrieve]
  14. Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., and Evans, R. M. (1992) Nature 355, 446-449[CrossRef][Medline] [Order article via Infotrieve]
  15. Zhang, X. K., Hoffman, B., Tran, P.-B. V., Graupner, G., and Pfahl, M. (1992) Nature 355, 442-446
  16. Bugge, T. H., Pohl, J., Lonnoy, O., and Stunnenberg, H. G. (1992) EMBO J. 11, 1409-1418[Medline] [Order article via Infotrieve]
  17. Sugawara, A., Yen, P. M., Darling, D. S., and Chin, W. W. (1993) Endocrinology 133, 965-971[Abstract/Free Full Text]
  18. Mangelsdorf, D. J., Borgmeyer, U., Heyman, R. A., Zhou, J. Y., Ong, E. S., Oro, A. E., Kakizuka, A., and Evans, R. M. (1992) Genes Dev. 6, 329-344[Abstract/Free Full Text]
  19. Mangelsdorf, D., and Evans, R. (1995) Cell 83, 841-850[CrossRef][Medline] [Order article via Infotrieve]
  20. Hsu, J.-H., Zavacki, A., Harney, J., and Brent, G. (1995) Endocrinology 136, 421-430[Abstract]
  21. Lee, I. J., Driggers, P. H., Medin, J. A., Nikodem, V. M., and Ozato, K. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1647-1651[Abstract/Free Full Text]
  22. Andersson, M. L., Nordström, K., Demczuk, S., Harbers, M., and Vennström, B. (1992) Nucleic Acids Res. 20, 4803-4810[Abstract/Free Full Text]
  23. Yen, P. M., Darling, D. S., Carter, R. L., Forgione, M., Umeda, P. K., and Chin, W. W. (1992) J. Biol. Chem. 267, 3565-3568[Abstract/Free Full Text]
  24. Ribeiro, R. C. J., Kushner, P. J., Apriletti, J. W., West, B. L., and Baxter, J. D. (1992) Mol. Endocrinol. 6, 1142-1152[Abstract/Free Full Text]
  25. Hörlein, A., Naar, A., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C., and Rosenfeld, M. (1995) Nature 377, 397-404[CrossRef][Medline] [Order article via Infotrieve]
  26. Chen, J., and Evans, R. (1995) Nature 377, 454-457[CrossRef][Medline] [Order article via Infotrieve]
  27. Onate, S., Tsai, S., Tsai, M.-J., and O'Malley, B. (1995) Science 270, 1354-1357[Abstract/Free Full Text]
  28. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R., Rose, D., Glass, C., and Rosenfeld, M. (1996) Cell 85, 1-12[CrossRef][Medline] [Order article via Infotrieve]
  29. Farsetti, A., Mitsuhashi, T., Desvergne, B., Robbins, J., and Nikodem, V. M. (1991) J. Biol. Chem. 266, 23226-23232[Abstract/Free Full Text]
  30. Strait, K., Carlson, D., Schwartz, H., and Oppenheimer, J. (1997) Endocrinology 138, 635-641[Abstract/Free Full Text]
  31. Farsetti, A., Desvergne, B., Hallenbeck, P., Robbins, J., and Nikodem, V. M. (1992) J. Biol. Chem. 267, 15784-15788[Abstract/Free Full Text]
  32. Desvergne, B., Petty, K. J., and Nikodem, V. M. (1991) J. Biol. Chem. 266, 1008-1013[Abstract/Free Full Text]
  33. Morioka, H., Tennyson, G. E., and Nikodem, V. M. (1988) Mol. Cell. Biol. 8, 3542-3545[Abstract/Free Full Text]
  34. Higuchi, R. (1989) in PCR Technology (Erlich, H. A., ed), pp. 61-70, W. H. Freeman and Co., New York
  35. Modak, S. P., Principaud, E., and Spohr, G. (1993) Oncogene 8, 645-654[Medline] [Order article via Infotrieve]
  36. IJpenberg, A., Jeannin, E., Wahli, W., and Desvergne, B. (1997) J. Biol. Chem. 272, 20108-20117[Abstract/Free Full Text]
  37. Le Ricousse, S., Gouilleux, F., Fortin, D., Joulin, V., and Richard-Foy, H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5072-5077[Abstract/Free Full Text]
  38. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164[Abstract/Free Full Text]
  39. Wong, J., Shi, Y.-B., and Wolffe, A. P. (1995) Genes Dev. 2696-2711
  40. Lazar, M. A., Berrodin, T. J., and Harding, H. P. (1991) Mol. Cell. Biol. 11, 5005-5015[Abstract/Free Full Text]
  41. Kim, H.-S., Crone, D. E., Sprung, C. N., Tillman, J. B., Force, W. R., Crew, M. D., Mote, P. L., and Spindler, S. R. (1992) Mol. Endocrinol. 6, 1489-1501[Abstract/Free Full Text]
  42. Katz, R. W., and Koenig, R. J. (1993) J. Biol. Chem. 268, 19392-19397[Abstract/Free Full Text]
  43. Schräder, M., Becker-André, M., and Carlberg, C. (1994) J. Biol. Chem. 269, 6444-6449[Abstract/Free Full Text]
  44. Miyamoto, T., Suzuki, S., and DeGroot, L. J. (1993) Mol. Endocrinol. 7, 224-231[Abstract/Free Full Text]
  45. Toyoda, N., Zavacki, A. M., Maia, A. L., Harney, J. W., and Larsen, P. R. (1995) Mol. Cell. Biol. 15, 5100-5112[Abstract]
  46. Darling, D. S., Carter, R. L., Yen, P. M., Welborn, J. M., Chin, W. W., and Umeda, P. K. (1993) J. Biol. Chem. 268, 10221-10227[Abstract/Free Full Text]
  47. Williams, G. R., Harney, J. W., Forman, B. M., Samuels, H. H., and Brent, G. A. (1991) J. Biol. Chem. 266, 19636-19644[Abstract/Free Full Text]
  48. Brent, G. A., Williams, G. R., Harney, J. W., Forman, B. M., Samuels, H. H., Moore, D. D., and Larsen, P. R. (1992) Mol. Endocrinol. 6, 502-514[Abstract/Free Full Text]
  49. Park, H.-Y., Davidson, D., Raaka, B. M., and Samuels, H. H. (1993) Mol. Endocrinol. 7, 319-330[Abstract/Free Full Text]
  50. Bhat, M., Ashizawa, K., and Cheng, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7927-7931[Abstract/Free Full Text]
  51. Katz, D., Reginato, M. J., and Lazar, M. A. (1995) Mol. Cell. Biol. 15, 2341-2348[Abstract]
  52. Kurokawa, R., Yu, V. C., Näär, A., Kyakumoto, S., Han, Z., Silverman, S., Rosenfeld, M. G., and Glass, C. K. (1993) Genes Dev. 7, 1423-1435[Abstract/Free Full Text]
  53. Yen, P. M., Ikeda, M., Wilcox, E. C., Brubaker, J. H., Spanjaard, R. A., Sugawara, A., and Chin, W. W. (1994) J. Biol. Chem. 269, 12704-12709[Abstract/Free Full Text]
  54. Wahlström, G. M., Sjöberg, M., Andersson, M., Nordström, K., and Vennström, B. (1992) Mol. Endocrinol. 6, 1013-1022[Abstract/Free Full Text]
  55. Medin, J. A., Minucci, S., Driggers, P. H., Lee, I. J., and Ozato, K. (1994) Mol. Cell. Endocrinol. 105, 27-35[CrossRef][Medline] [Order article via Infotrieve]
  56. Forman, B. M., Umesono, K., Chen, J., and Evans, R. M. (1995) Cell 81, 541-550[CrossRef][Medline] [Order article via Infotrieve]
  57. Katz, R. W., and Koenig, R. J. (1994) J. Biol. Chem. 269, 18915-18920[Abstract/Free Full Text]
  58. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and Tung, L. (1996) Mol. Endocrinol. 10, 1167-1177[Abstract/Free Full Text]
  59. Kurokawa, R., Soderstrom, M., Horlein, A., Halachmi, S., Brown, M., Rosenfeld, M., and Glass, C. (1995) Nature 377, 451-454[CrossRef][Medline] [Order article via Infotrieve]
  60. Chakravarti, D., LaMorte, V., Nelson, M., Nakajima, T., and Schulman, I. (1996) Nature 383, 99-103[CrossRef][Medline] [Order article via Infotrieve]
  61. Zamir, I., Zhang, J., and Lazar, M. (1997) Genes Dev. 11, 835-846[Abstract/Free Full Text]
  62. Nawaz, Z., Tsai, M.-J., and O'Malley, B. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11691-11695[Abstract/Free Full Text]
  63. Tong, G.-X., Jeyakumar, M., Tanen, M., and Bagchi, M. (1996) Mol. Cell. Biol. 16, 1909-1920[Abstract]
  64. Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., and Moras, D. (1995) Nature 378, 681-689[CrossRef][Medline] [Order article via Infotrieve]
  65. Henttu, P., Kalkhoven, E., and Parker, M. (1997) Mol. Cell. Biol. 17, 1832-1839[Abstract]
  66. Strait, K., Zou, L., and Oppenheimer, J. (1992) Mol. Endocrinol. 6, 1874-1880[Abstract/Free Full Text]
  67. Yarwood, N., Gurr, J., Sheppard, M., and Franklyn, J. (1993) J. Biol. Chem. 268, 21984-21989[Abstract/Free Full Text]
  68. Wilson, T. E., Paulsen, R. E., Padgett, K. A., and Milbrandt, J. (1992) Science 256, 107-110[Abstract/Free Full Text]
  69. Rastinejad, F., Perlmann, T., Evans, R., and Sigler, P. (1995) Nature 375, 203-211[CrossRef][Medline] [Order article via Infotrieve]
  70. Dollé, P., Fraulob, V., Kastner, P., and Chambon, P. (1994) Mech. Dev. 45, 91-104[CrossRef][Medline] [Order article via Infotrieve]
  71. Lefstin, J. A., and Yamamoto, K. R. (1998) Nature 392, 885-888[CrossRef][Medline] [Order article via Infotrieve]
  72. Krey, G., Mahfoudi, A., and Wahli, W. (1995) Mol. Endocrinol. 9, 219-231[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. N. Feige, L. Gelman, D. Rossi, V. Zoete, R. Metivier, C. Tudor, S. I. Anghel, A. Grosdidier, C. Lathion, Y. Engelborghs, et al.
The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor {gamma} Modulator That Promotes Adipogenesis
J. Biol. Chem., June 29, 2007; 282(26): 19152 - 19166.
[Abstract] [Full Text] [PDF]


Home page
Integr. Comp. Biol.Home page
T. Flatt, L. L. Moroz, M. Tatar, and A. Heyland
Comparing thyroid and insect hormone signaling
Integr. Comp. Biol., December 1, 2006; 46(6): 777 - 794.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. M. Schoonover, M. M. Seibel, D. M. Jolson, M. J. Stack, R. J. Rahman, S. A. Jones, C. N. Mariash, and G. W. Anderson
Thyroid Hormone Regulates Oligodendrocyte Accumulation in Developing Rat Brain White Matter Tracts
Endocrinology, November 1, 2004; 145(11): 5013 - 5020.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. C. Helbing, K. Werry, D. Crump, D. Domanski, N. Veldhoen, and C. M. Bailey
Expression Profiles of Novel Thyroid Hormone-Responsive Genes and Proteins in the Tail of Xenopus laevis Tadpoles Undergoing Precocious Metamorphosis
Mol. Endocrinol., July 1, 2003; 17(7): 1395 - 1409.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
I. Dussault, M. Lin, K. Hollister, M. Fan, J. Termini, M. A. Sherman, and B. M. Forman
A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity
Mol. Cell. Biol., August 1, 2002; 22(15): 5270 - 5280.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. Guissouma, S. M. Dupre, N. Becker, E. Jeannin, I. Seugnet, B. Desvergne, and B. A. Demeneix
Feedback on Hypothalamic TRH Transcription Is Dependent on Thyroid Hormone Receptor N Terminus
Mol. Endocrinol., July 1, 2002; 16(7): 1652 - 1666.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Weber, U. Zimmermann, H. Winter, A. Mack, I. Kopschall, K. Rohbock, H.-P. Zenner, and M. Knipper
Thyroid hormone is a critical determinant for the regulation of the cochlear motor protein prestin
PNAS, February 20, 2002; (2002) 52609899.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. Rusch, L. Ng, R. Goodyear, D. Oliver, I. Lisoukov, B. Vennstrom, G. Richardson, M. W. Kelley, and D. Forrest
Retardation of Cochlear Maturation and Impaired Hair Cell Function Caused by Deletion of All Known Thyroid Hormone Receptors
J. Neurosci., December 15, 2001; 21(24): 9792 - 9800.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. M. Yen
Physiological and Molecular Basis of Thyroid Hormone Action
Physiol Rev, July 1, 2001; 81(3): 1097 - 1142.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Martín, M. L. Cortés, Pablo de Felipe, A. Farsetti, N. B. Calcaterra, and M. Izquierdo
Cancer Gene Therapy by Thyroid Hormone-mediated Expression of Toxin Genes
Cancer Res., June 1, 2000; 60(12): 3218 - 3224.
[Abstract] [Full Text]


Home page
Mol. Cell. Biol.Home page
J. Zhang, X. Hu, and M. A. Lazar
A Novel Role for Helix 12 of Retinoid X Receptor in Regulating Repression
Mol. Cell. Biol., September 1, 1999; 19(9): 6448 - 6457.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Wu, P. Delerive, W. W. Chin, and T. P. Burris
Requirement of Helix 1 and the AF-2 Domain of the Thyroid Hormone Receptor for Coactivation by PGC-1
J. Biol. Chem., March 8, 2002; 277(11): 8898 - 8905.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Weber, U. Zimmermann, H. Winter, A. Mack, I. Kopschall, K. Rohbock, H.-P. Zenner, and M. Knipper
Thyroid hormone is a critical determinant for the regulation of the cochlear motor protein prestin
PNAS, March 5, 2002; 99(5): 2901 - 2906.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeannin, E.
Right arrow Articles by Desvergne, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeannin, E.
Right arrow Articles by Desvergne, B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement